Targeting histone deacetylase in thyroid cancer
- 11 December 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 17 (2) , 179-193
Abstract
Introduction: Epigenetic changes have been detected in thyroid cancer cells, and evidence indicates that they may contribute to altered differentiation and proliferation of these cells. Histone acetylation/deacetylation represents a major mechanism for modulating the expression of genes, including those involved in neoplastic transformation, and drugs that inhibit histone deacetylase (HDAC) activity have displayed promising anti-tumor activity in many pre-clinical studies. Areas covered: We provide a brief overview of the mechanisms underlying histone acetylation-mediated regulation of gene expression and the principal epigenetic alterations detected in thyroid cancer cells. The review then focuses on the results of pre-clinical and clinical studies (some still underway) in which HDAC inhibitors (HDACi) have been used to treat thyroid cancer. Expert opinion: HDACs are a potentially important target for thyroid cancer treatments. Inhibition of HDAC activity has produced encouraging results in terms of reducing proliferation rates and restoring the iodine-uptake capacity in transformed thyrocytes. HDACi, especially when combined with other molecularly targeted drugs, may represent an important option for those tumors that are unresponsive to the currently available treatments.Keywords
This publication has 105 references indexed in Scilit:
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancerEuropean Journal of Endocrinology, 2012
- Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapyOncogene, 2011
- HDACs link the DNA damage response, processing of double-strand breaks and autophagyNature, 2011
- Nuclear protein isoforms: Implications for cancer diagnosis and therapyJournal of Cellular Biochemistry, 2010
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effectInvestigational New Drugs, 2010
- Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancersNature Reviews Cancer, 2010
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- An Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone FunctionMolecular Cell, 2007
- The epigenetic progenitor origin of human cancerNature Reviews Genetics, 2006